Skip to content
Clinical Trials – home
Verifiedinfo

Unidade Local De Saude De Loures-Odivelas EPE

Portugal Avenida Carlos Teixeira, 2674-514 Loures, Portugal

  • 24 trials recruiting
  • Non-small cell lung cancer · Idiopathic pulmonary fibrosis · Focal segmental glomerulosclerosis
  • Adults and children

About Specializations

Unidade Local De Saude De Loures-Odivelas EPE in Loures, Portugal specialises in clinical trials of conditions such as Non-small cell lung cancer, Idiopathic pulmonary fibrosis, Focal segmental glomerulosclerosis, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Breast Cancer Research

The Medical Oncology team at Unidade Local De Saude De Loures-Odivelas EPE is actively involved in studies for neoplasms, with a strong focus on breast cancer and non-small cell lung cancer. These trials are designed to test new treatment approaches and compare them with current standards to improve disease control and survival.

  • Advanced and metastatic breast cancer, including HER2-positive, HER2-negative, and hormone receptor-positive disease
  • Evaluating new therapies and treatment combinations to improve progression-free survival and overall outcomes
  • Research in early and advanced-stage disease, including patients at high risk of recurrence

These studies reflect a broad effort to refine cancer care through more effective and better-targeted treatment options.

Lung Cancer and Respiratory Disease Trials

Research in respiratory tract diseases and neoplasms includes trials in non-small cell lung cancer, lung cancer, idiopathic pulmonary fibrosis, and progressive pulmonary fibrosis. The main goal is to evaluate new therapies that may slow disease progression, improve breathing-related outcomes, and extend survival.

  • Non-small cell lung cancer, including locally advanced, metastatic, and EGFR-mutated disease
  • Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, focusing on lung function and disease stabilization
  • Testing novel treatment combinations and supportive approaches for difficult-to-treat respiratory conditions

This area highlights the site’s interest in both cancer and chronic lung disease research, with studies aimed at improving treatment effectiveness.

Gastroenterology and Inflammatory Bowel Disease

The site also contributes to studies in digestive system diseases and immune system diseases, especially Crohn's disease, ulcerative colitis, and eosinophilic esophagitis. These trials are intended to assess whether new therapies can reduce inflammation, control symptoms, and support long-term remission.

  • Crohn's disease and ulcerative colitis in moderate to severe forms
  • Eosinophilic esophagitis, with a focus on improving swallowing-related inflammation
  • Evaluating maintenance strategies and long-term disease control

At Unidade Local De Saude De Loures-Odivelas EPE, this research area supports more personalized care for chronic inflammatory bowel conditions.

Kidney and Cardiovascular Medicine

Clinical trials in cardiovascular diseases and kidney-related conditions are examining chronic kidney disease, focal segmental glomerulosclerosis, atherosclerotic cardiovascular disease, and hypertension. The focus is on protecting organ function, reducing inflammation, and lowering the risk of major cardiovascular events.

  • Chronic kidney disease and focal segmental glomerulosclerosis, with attention to kidney function preservation
  • Hypertension and high cardiovascular risk, aiming to reduce serious heart and stroke outcomes
  • Studying therapies that may improve both kidney and heart health

These studies show a strong interest in chronic disease prevention and long-term risk reduction.

Neurology and Stroke Recovery

Research in nervous system diseases includes studies in acute ischemic stroke, primary progressive multiple sclerosis, multiple system atrophy, and upper limb spasticity after stroke or traumatic brain injury. The purpose of these trials is to improve recovery, slow neurological decline, and address disabling symptoms.

  • Acute ischemic stroke, focusing on better functional recovery after the event
  • Primary progressive multiple sclerosis, aiming to delay worsening disability
  • Upper limb spasticity, evaluating options to reduce muscle stiffness and improve movement

This field brings together acute care and chronic neurological disease management in a way that may benefit patients with very different needs.

Airway, Ear-Nose-Throat, and Allergy-Related Care

The site participates in trials across respiratory tract diseases, otorhinolaryngologic diseases, and immune system diseases, including chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease, and alpha-1 antitrypsin deficiency. These studies are designed to improve symptom control and support better day-to-day breathing and quality of life.

  • Chronic rhinosinusitis with nasal polyps, with a focus on reducing congestion and polyp burden
  • Chronic obstructive pulmonary disease and alpha-1 antitrypsin deficiency, exploring new ways to manage chronic lung disease
  • Testing therapies aimed at improving respiratory comfort and long-term disease control

This area shows a practical focus on chronic airway conditions that can significantly affect everyday functioning.

Psychiatry, Migraine, and Sleep-Related Research

Clinical research at the site also covers mental disorders and other quality-of-life conditions such as major depressive disorder with insomnia symptoms and menstrual migraine. The aim is to evaluate treatments that may relieve symptoms, improve sleep, and reduce the burden of recurrent headaches and mood disorders.

  • Major depressive disorder with insomnia symptoms, studying add-on treatment approaches
  • Menstrual migraine, focusing on prevention of migraine attacks
  • Assessing whether new therapies can improve daily functioning and symptom relief

These studies expand the site’s portfolio beyond oncology and internal medicine into conditions that affect both mental and physical well-being.

Eye Disease and Vision Research

There is also activity in eye diseases, including polypoidal choroidal vasculopathy. The research is intended to determine whether new treatment options can improve vision and help preserve eye health in patients with symptomatic retinal disease.

  • Polypoidal choroidal vasculopathy, a retinal condition that can affect central vision
  • Evaluating therapies aimed at improving visual outcomes
  • Supporting research into better management of chronic eye disease

This smaller but important area reflects the site’s wider interest in specialized, patient-centered clinical research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenida Carlos Teixeira2674-514 LouresPortugal
Recruiting now
24 trials
Conditions studied
30
Partner status
Verified

More sites in LouresPortugal

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

41 clinical trials

Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ZILEBESIRAN
  • Sponsor:Alnylam Pharmaceuticals Inc.
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.
Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:SELTOREXANT
  • Sponsor:Janssen - Cilag International
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.
Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:F. Hoffmann-La Roche AG
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.